Abstract
IMPORTANCE Avoidant restrictive food intake disorder (ARFID) is characterized by an extremely limited range and/or amount of food eaten, resulting in the persistent failure to meet nutritional and/or energy needs. Its etiology is poorly understood and knowledge of genetic and environmental contributions to ARFID is needed to guide future research.
OBJECTIVE To determine the extent to which genetic and environmental factors contribute to the liability to the broad ARFID phenotype.
DESIGN, SETTING, AND PARTICIPANTS A nationwide Swedish twin cohort including 16,951 twin pairs born 1992-2010 whose parents participated in the Child and Adolescent Twin Study in Sweden (CATSS) at twin age 9 or 12 years (49.4% female). CATSS was linked to the National Patient Register (NPR) and the Prescribed Drug Register (PDR).
MAIN OUTCOME/MEASURES From CATSS, NPR, and PDR, we extracted all parent-reports, diagnoses, procedures, and prescribed drugs between age 6 and 12 that were relevant to the DSM-5 ARFID criteria and developed a composite measure for the ARFID phenotype (i.e., avoidant/restrictive eating with clinically significant impact such as low weight or nutritional deficiency, and with fear of weight gain as an exclusion). In sensitivity analyses, we controlled for autism and medical conditions that could account for the eating disturbance. We fitted univariate liability threshold models to estimate the relative contribution of genetic and environmental variation to the liability to the ARFID phenotype.
RESULTS We identified 667 children (2.0%, 38.2% female) with the ARFID phenotype between age 6 and 12. Variation in the liability to ARFID was largely explained by additive genetic factors (0.79, 95% confidence interval [CI] 0.71-0.86), with significant contributions from non-shared environmental factors (0.21, 95% CI 0.14-0.29). Heritability was very similar when excluding children with autism (0.77, 95% CI 0.67-0.84) or medical illnesses that could account for the eating disturbance (0.80, 95% CI 0.71-0.86).
CONCLUSIONS AND RELEVANCE Prevalence and sex distribution of the broad ARFID phenotype were similar to previous studies, supporting the use of existing epidemiological data to identify ARFID. This first study of the genetic and environmental etiology of ARFID suggests that ARFID is highly heritable, encouraging future twin and molecular genetic studies.
Competing Interest Statement
Dr Dinkler reports speaker fees from Baxter Medical AB and Fresenius Kabi AB. Dr Larsson reports receiving grants from Shire Pharmaceuticals; personal fees from and serving as a speaker for Medice, Shire/Takeda Pharmaceuticals and Evolan Pharma AB; and sponsorship for a conference on attention-deficit/hyperactivity disorder from Shire/Takeda Pharmaceuticals and Evolan Pharma AB, all outside the submitted work. Henrik Larsson is editor-in-chief of JCPP Advances. Dr Bulik reports: Shire (grant recipient, Scientific Advisory Board member); Lundbeckfonden (grant recipient); Pearson (author, royalty recipient). All grants and fees were received outside the submitted work. No other disclosures were reported.
Funding Statement
CMB Is supported by NIMH (R56MH129437; R01MH120170; R01MH124871; R01MH119084; R01MH118278; R01 MH124871); Brain and Behavior Research Foundation Distinguished Investigator Grant; Swedish Research Council (538-2013-8864); and Lundbeck Foundation (R276-2018-4581). LD is supported by the Mental Health Foundation (2022) and Fredrik and Ingrid Thurings Foundation (2021-00660). The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research was approved by the Regional Ethical Review Board in Stockholm, Sweden (02-289, 03-672, 2010/322-31/2, 2010/597-31/1, 2016/2135-31, 2018/1398-32).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Due to ethical restrictions related to protecting confidentiality connected to the Swedish Twin Registry, relevant data are available on request pending approval from the Swedish Twin Registry.
